Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
CEP-9722 is an inhibitor of poly-adenosine diphosphate (ADP) ribose polymerase -1 and -2
(PARP). The primary purpose of this study is to (Part 1) determine the maximum tolerated dose
(MTD) of CEP-9722 administered daily to patients with advanced or metastatic solid tumors,
(Part 2) to evaluate the safety and tolerability of that dose, and to investigate whether
CEP-9722 has antitumor activity as a single agent.